Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
136 hedge funds and large institutions have $863M invested in Acceleron Pharma in 2017 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 45 increasing their positions, 46 reducing their positions, and 25 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
5% more capital invested
Capital invested by funds: $826M → $863M (+$37.6M)
2% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 46
7% less funds holding
Funds holding: 146 → 136 (-10)
16% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 25
50% less call options, than puts
Call options by funds: $1.14M | Put options by funds: $2.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$94.8M |
| 2 |
AG
Artal Group
Luxembourg
|
+$15.8M |
| 3 |
Millennium Management
New York
|
+$13.8M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$9.49M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$8.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
-$23.1M |
| 2 |
JP Morgan Chase
New York
|
-$18.5M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$13M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.6M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$9.45M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Capital Fund Management (CFM)
Paris,
France
| – | -$498K | -19,496 | Closed |
|
|
ARTA
152
A.R.T. Advisors
New York
| – | -$487K | -19,100 | Closed |
|
153
AQR Capital Management
Greenwich,
Connecticut
| – | -$474K | -18,568 | Closed |
|
|
VKH
154
Virtu KCG Holdings
New York
| – | -$387K | -15,165 | Closed |
|
155
Bessemer Group
Woodbridge,
New Jersey
| – | -$122K | -4,755 | Closed |
|
|
NIT
156
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| – | -$92K | -3,600 | Closed |
|
|
TRCT
157
Tower Research Capital (TRC)
New York
| – | -$25K | -993 | Closed |
|
|
SFS
158
Sowell Financial Services
North Little Rock,
Arkansas
| – | -$5K | -168 | Closed |
|
159
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$1K | -72 | Closed |
|
|
BBHC
160
Brown Brothers Harriman & Co
New York
| – | -$2K | -71 | Closed |
|
|
IA
161
IFP Advisors
Tampa,
Florida
| – | -$395 | -15 | -71% |
|
XLRN Hedge Fund Activity: Q1 2017 in Review
136 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q1 2017, worth a combined $863M — up 4.5% from $826M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of XLRN and 21 opened new positions — a net loss of 4 holders — while 46 trimmed existing stakes and 45 added.
The largest buyer was BlackRock, adding an estimated $94.8M. The largest seller was Oak Ridge Investments, cutting an estimated $23.1M.
- 136 institutional investors held Acceleron Pharma (XLRN) as of Q1 2017, down from 146 in Q4 2016.
- Funds reported $863M of Acceleron Pharma stock for Q1 2017, up 4.5% quarter-over-quarter.
- 21 funds opened new Acceleron Pharma positions in Q1 2017 and 25 closed out, a net change of -4 holders.
- The largest Acceleron Pharma buyer in Q1 2017 was BlackRock, an estimated $94.8M added.
- The largest Acceleron Pharma seller in Q1 2017 was Oak Ridge Investments, an estimated $23.1M sold.
Based on aggregated 13F filings for Q1 2017.